Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Figure 1

Reactivity of several anti-mucin MAbs with a high molecular weight mucin containing fraction (CPM1) isolated from the Capan-1 human pancreatic adenocarcinoma. MAbs are identified by clone name with reactive species of mucin indicated by horizontal bars beneath MAb clone names (MUC1, etc.). In addition to PAM4, substantial reactions were observed for anti-MUC1, -MUC5AC, and -CEACAM6 antibodies. All MAbs were employed at a concentration of 10 μg/mL.

Back to article page

Molecular Cancer

ISSN: 1476-4598